Kenneth K Kwok
Overview
Explore the profile of Kenneth K Kwok including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
56
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Baraliakos X, Szumski A, Kwok K, Vlahos B, Borlenghi C
Rheumatol Ther
. 2024 Mar;
11(3):583-597.
PMID: 38488976
Introduction: Short-term placebo (PBO)- or active-controlled clinical studies have demonstrated that etanercept (ETN) is effective and well tolerated in patients with radiographic axial spondyloarthritis (r-axSpA) with long-term efficacy and safety...
2.
Schreiber S, Rubin D, Ng S, Peyrin-Biroulet L, Danese S, Modesto I, et al.
J Crohns Colitis
. 2023 Jul;
17(11):1761-1770.
PMID: 37402275
Background And Aims: Patients with inflammatory bowel disease have increased risk of atherosclerotic cardiovascular [CV] disease [ASCVD]. Tofacitinib is an oral Janus kinase inhibitor for the treatment of ulcerative colitis...
3.
Loftus E, Baumgart D, Gecse K, Kinnucan J, Connelly S, Salese L, et al.
Inflamm Bowel Dis
. 2022 Jul;
29(5):744-751.
PMID: 35792493
Background: Tofacitinib is an oral, small molecule Janus kinase inhibitor for the treatment of ulcerative colitis (UC). Patients with inflammatory bowel disease are susceptible to Clostridium difficile infection (CDI). Here,...
4.
Rubin D, Modesto I, Vermeire S, Danese S, Ng S, Kwok K, et al.
Aliment Pharmacol Ther
. 2021 Oct;
55(3):302-310.
PMID: 34626429
Background: Tofacitinib is an oral Janus kinase inhibitor for the treatment of ulcerative colitis (UC). Post-marketing surveillance (PMS) is an important part of monitoring adverse events (AEs). Aims: To report...
5.
Dombi T, Kwok K, Sultan M
BMC Ophthalmol
. 2012 Aug;
12:37.
PMID: 22871086
Background: To evaluate the safety of pegaptanib sodium 0.3 mg intravitreal injection in the treatment of neovascular age-related macular degeneration in subjects with or without diabetes mellitus. Methods: A pooled,...
6.
Tressler C, Wiseman R, Dombi T, Jessen B, Huang K, Kwok K, et al.
Br J Ophthalmol
. 2011 Apr;
95(11):1490-5.
PMID: 21515566
Aim: To determine if there is an association between the use of latanoprost ophthalmic solution and malignant melanoma and to assess the evidence of a plausible biological mechanism. Methods: Two...
7.
Alm A, Grunden J, Kwok K
J Glaucoma
. 2010 Jun;
20(4):215-22.
PMID: 20520568
Purpose: To evaluate the safety of fixed-combination latanoprost/timolol (Xalacom) in patients requiring additional intraocular pressure (IOP) reduction over 5 years. Methods: This phase 3b, open-label, multicenter study included prostaglandin-naive participants...
8.
Higginbotham E, Olander K, Kim E, Grunden J, Kwok K, Tressler C
Arch Ophthalmol
. 2010 Feb;
128(2):165-72.
PMID: 20142538
Objective: To assess the efficacy and safety of fixed-combination latanoprost-timolol (FCLT) vs latanoprost or timolol monotherapy. Methods: This 12-week, randomized, double-masked, parallel-group study included patients with open-angle glaucoma or ocular...
9.
Palmberg P, Kim E, Kwok K, Tressler C
Eur J Ophthalmol
. 2010 Jan;
20(4):708-18.
PMID: 20099236
Purpose: To evaluate the efficacy and safety of fixed combination latanoprost/timolol versus latanoprost or timolol monotherapy. Methods: This 12-week, randomized, double-masked study was designed to overcome potential shortcomings of previous...